Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

- PMLiVE

EMA starts review of Pfizer and Merck’s PD-L1 inhibitor

Avelumab looks set to be the first new drug to treat Merkel cell carcinoma

Bristol-Myers Squibb (BMS) building

Opdivo drives gain in BMS sales, but business revamp coming

Plans to invest in biologics production with potential divestment of older brands

AstraZeneca AZ

AstraZeneca shaken by FDA partial hold on durvalumab trial

Aims to resume trial recruitment as soon as possible after bleeding side effects curb study

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

Bristol-Myers Squibb (BMS) building

Keytruda, Opdivo narrow Tecentriq’s lead in bladder cancer

BMS’ drug is currently under FDA and EMA review in advanced urothelial carcinoma

Bristol-Myers Squibb (BMS) building

NICE U-turn on Opdivo for kidney cancer

BMS sways the watchdog with new data and a patient access scheme

Roche Basel Switzerland

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

EU flag

Italian pharma scandals prompts call for EU-wide pricing probe

Aspen fined €5.2m for threat to halt supply of cancer drugs if price hikes not accepted

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

Bristol-Myers Squibb (BMS) building

Opdivo data confirms poor showing in first-line NSCLC

Lung cancer drug failed to outperform both chemotherapy and Merck & Co’s Keytruda

National Institute for Health and Care Excellence NICE logo

NICE turns down Keytruda for lung cancer in draft guidance

Says long-term benefits for advanced non-small cell lung cancer treatment not proven

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links